Read twice and referred to the Committee on Commerce, Science, and Transportation.
The Genomic Data Protection Act requires direct-to-consumer genomic testing companies to let consumers access and, with limited exceptions, delete their genomic data and request destruction of biological samples. Companies must provide clear notices, fulfill deletion or destruction requests within 30 days, and notify consumers when completed.
Privacy control versus regulatory burden on businesses
Consumer privacy appeal balanced by industry resistance and debates over regulatory reach and preemption.
The Genomic Data Protection Act requires direct-to-consumer genomic testing companies to let consumers access and, with limited exceptions, delete their genomic data and request destruction of biological samples.
Companies must provide clear notices, fulfill deletion or destruction requests within 30 days, and notify consumers when completed.
Deidentified genomic data may be shared for research consistent with HIPAA deidentification rules; the FTC enforces violations as unfair or deceptive practices.
Narrow, administrable privacy bill with clear protections but faces industry pushback and general Congressional inertia on standalone privacy legislation.
How solid the drafting looks.
Privacy control versus regulatory burden on businesses
These are examples from the analysis, not a ranked list of the most-affected groups.
Privacy control versus regulatory burden on businesses
Likely supportive because the bill strengthens individual control over sensitive genomic information and limits corporate retention.
Would welcome the right-to-delete and sample-destruction provisions while seeking stronger safeguards against reidentification and robust enforcement.
Generally favorable to consumer privacy improvements, but cautious about operational burdens and clarity.
Views the 30-day requirement and FTC enforcement as reasonable, while seeking implementation guidance and cost/feasibility analysis for businesses.
Skeptical because the bill imposes new federal mandates on businesses and expands FTC regulatory authority.
Concerned it will increase compliance costs, hamper innovation, and create legal uncertainty for genomic firms.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, administrable privacy bill with clear protections but faces industry pushback and general Congressional inertia on standalone privacy legislation.
The bill has not accumulated any surfaced votes yet.
Privacy control versus regulatory burden on businesses
Narrow, administrable privacy bill with clear protections but faces industry pushback and general Congressional inertia on standalone priva…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Genomic Data Protection Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.